A 1:1 ratio of THC to CBD proved superior to a 4:1 ratio.
Therapy intensification with carboplatin improved five-year event-free survival in children with high-risk group 3 medulloblastoma only.
While there is short-term excess mortality, cumulative survival is similar to the general population.
The benefit was restricted to patients with IDH1/2-mutant tumors.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
There was no improvement in progression-free or overall survival with marizomib.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Early radiotherapy may preserve visual acuity for certain children with sporadic optic pathway/hypothalamic gliomas.
The proportion of childhood medulloblastomas varied widely between countries, offsetting the low proportion of low-grade astrocytomas in several countries.
Researchers found that the therapy did not improve EFS or OS in high-risk patients and also led to an increase in toxic side effects.
Investigators sought to determine the prevalence of weight gain and becoming overweight or obese and its association with hypothalamic-pituitary dysfunction in survivors of childhood brain cancer.
Oblato plans to evaluate OKN-007 for diffuse intrinsic pontine glioma in a phase 1/2 trial this year.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Investigators performed immunohistochemistry on glioblastoma tumor samples in an effort to identify molecular subtypes associated with treatment sensitivities.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Approval was based on results from two phase 2 single-arm, open-label trials that demonstrated overall response rate and duration of response.